Key result
3-methyl-4-aminopyridine (3Me4AP) was approximately 7-fold more potent than 4AP at blocking voltage-gated potassium channels, suggesting its potential as a candidate for therapy and imaging.
Why the study?
Following findings that [18F]3F4AP can be used as a PET tracer for demyelinated lesions, novel 4-aminopyridine derivatives were investigated as potential candidates for PET imaging and therapy.
Answers are grounded in this paper and cite their sources.
Novel 4-aminopyridine derivatives, particularly 3Me4AP, demonstrate potent voltage-gated potassium channel blockade, highlighting their potential as candidates for PET imaging and therapy in demyelinating diseases.
Abstract 4-Aminopyridine (4AP) is a specific blocker of voltage-gated potassium channels (K V 1 family) clinically approved for the symptomatic treatment of patients with multiple sclerosis (MS). It has recently been shown that [ 18 F]3F4AP, a radiofluorinated analog of 4AP, also binds to K V 1 channels and can be used as a PET tracer for the detection of demyelinated lesions in rodent models of MS. Here, we investigate four novel 4AP derivatives containing methyl (-CH 3 ), methoxy (-OCH 3 ) as well as trifluoromethyl (-CF 3 ) in the 2 and 3 position as potential candidates for PET imaging and/or therapy. We characterized the physicochemical properties of these compounds (basicity and lipophilicity) and analyzed their ability to block Shaker K + channel under different voltage and pH conditions. Our results demonstrate that three of the four derivatives are able to block voltage-gated potassium channels. Specifically, 3-methyl-4-aminopyridine (3Me4AP) was found to be approximately 7-fold more potent than 4AP and 3F4AP; 3-methoxy- and 3-trifluoromethyl-4-aminopyridine (3MeO4AP and 3CF 3 4AP) were found to be about 3- to 4-fold less potent than 4AP; and 2-trifluoromethyl-4-AP (2CF 3 4AP) was found to be about 60-fold less active. These results suggest that these novel derivatives are potential candidates for therapy and imaging.
No takes yet. Share an insight, caveat, or question.
Rodríguez-Rangel et al. (2020) studied Multiple Sclerosis (preclinical model). 4-aminopyridine derivatives (3Me4AP, 3MeO4AP, 3CF34AP, 2CF34AP) vs. 4AP and 3F4AP was evaluated on Half-maximal inhibitory concentration (IC50) for blocking Shaker K+ channels. 3-methyl-4-aminopyridine (3Me4AP) was approximately 7-fold more potent than 4AP at blocking voltage-gated potassium channels, suggesting its potential as a candidate for therapy and imaging.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: